Haier Bio intends to sell its stake in the U.S. company

January 21, Haier Bio announced its plans to sell its stake in the U.S. company. According to the announcement, the transaction is expected to increase Haier Bio's 2021 pre-tax investment income by about RMB349 million, although the exact amount will be determined by the company after the final price received for the transaction. In addition, Haier Bio said the proceeds from the exchange will be used to develop the company's main business.According to the announcement, Haier Bio recently received notice from Mesa, a U.S. subsidiary, that Thermo Fisher intends to acquire a full stake in Mesa and has signed a merger agreement that applies to U.S. Delaware law. Thermo Fisher will acquire Mesa 100% with the consent of shareholders who own more than half of Mesa's total voting rights, in accordance with the terms of the merger agreement and applicable laws of the State of Delaware.Haier Bio invested a total of US$20 million in Mesa, directly and indirectly, between June and November 2018. As of the date of disclosure of this announcement, the Company holds a total of 17.11% of Mesa's shares. Of these, Haier Bio owns 14.54 per cent of Mesa and Limited owns 2.57 per cent through Haier BioMedical HK Co., a wholly owned subsidiary.Founded in 2015, Mesa is primarily engaged in the development and production of molecular diagnostics and POCT (instant inspection)-related products. It is understood that as of September 30, 2020, Mesa had total assets of $28,923.4 million, total liabilities of $11.9515 million and net profit of $16.9719 million. Operating income for the January-September 2020 period was $34,128.3 million and net profit was $14,441,100, but Haier Said the figures were unaudited. (Sina Pharmaceutical News)